Nov 10, 2020 12:00 PM
Richard Zahn
Molecules to Medicines: Trends, technology and how do we pay?

Richard W. Zahn is a principal with HMJ Global Partners, a corporate strategy and governance group. Mr. Zahn has guided public and private companies in the U.S., Canada, United Kingdom, Australia, Europe, and Asia. Prior experience includes over four decades in pharmaceutical leadership including the founding management board member of Ortho Biotech, the biotechnology division of Johnson & Johnson, where he commercialized the world’s first monoclonal antibody and recombinant protein for human therapeutic use.

Mr. Zahn is the retired President of Schering Laboratories where he led change and grew the business to a $6 billion, 7000 employee integrated pharmaceutical research development and manufacturing organization. His portfolio included leading modalities in cardiovascular, oncology, allergy, and asthma.

Mr. Zahn has been a guest lecturer at leading universities discussing health policy and global impact. He is active in community groups, a member of the Iola Rotary Club and a Paul Harris Fellow.